-
Triacetin: From Acetate Donor to Assay Insight
2026-09-14
Triacetin, or glyceryl triacetate, is more than a formulation excipient: it is an acetate-bearing perturbagen that can connect metabolic, epigenetic, and cancer assays. This evidence-led guide explains how to interpret its biology, select experimental contexts, and avoid confusing solvent effects with mechanism.
-
Cholecystokinin Octapeptide Ammonium Workflow
2026-09-14
Build more informative CCK assays by pairing CCK-8 ammonium exposure with receptor controls, secreted-factor measurements, and pathway-resolved readouts. This guide translates the atrial ANP study into practical workflows while addressing peptide handling, concentration selection, and cross-model interpretation.
-
EV-ACLY Drives TAM Differentiation in HCC
2026-09-13
The reference study identifies extracellular vesicle-delivered ATP-citrate lyase as a metabolic signal that converts monocytes into immunosuppressive tumor-associated macrophages in hepatocellular carcinoma. By engineering CD81-decorated liposomal vesicles to deliver ACLY or its inhibitor, the authors connect palmitate-dependent protein S-palmitoylation with tumor progression and improved anti-PD-1/PD-L1 responses.
-
Stable Isotope UHPLC–MS/MS for Methylated Purines
2026-09-12
Zhang, Zhang, and Wang developed a stable isotope-diluted UHPLC–ESI-MS/MS method for quantifying 12 purine ribonucleosides, including 10 methylated species, in cultured-cell extracts. Ammonium bicarbonate-enhanced ionization, chromatographic resolution of isomers, methanol extraction, and solid-phase cleanup together improved sensitivity and enabled measurement of low-abundance RNA-derived nucleosides.
-
Merimepodib (VX-497): Translational IMPDH Strategy
2026-09-12
Merimepodib (VX-497) offers a mechanistically coherent way to interrogate guanine nucleotide dependence across antiviral, immunology, and cell-proliferation models. This thought-leadership article connects IMPDH biology with PEDV replication, experimental validation, translational positioning, and practical assay strategy while distinguishing research opportunity from clinical evidence.
-
Acetylspiramycin Workflows for Resistance Research
2026-09-11
Acetylspiramycin (Spiramycin B) connects ribosome-focused antimicrobial testing with practical studies of resistance and host response. This guide covers solvent handling, broth microdilution design, biosynthetic context, and troubleshooting for more interpretable experiments.
-
Bestatin (Ubenimex): Applied Research Workflows
2026-09-11
Bestatin (Ubenimex) enables selective aminopeptidase inhibition across enzyme, cell-based, apoptosis, and multidrug resistance workflows. This guide translates its potency profile and formulation requirements into practical assay design, controls, and troubleshooting strategies for reproducible cancer research.
-
CHI3L1-IN-5: Astrocyte Assay Workflow
2026-09-10
CHI3L1-IN-5 (Compound Z17) supports a differentiated neuroinflammation workflow by linking CHI3L1-mediated NF-κB suppression with astrocyte Aβ uptake and lysosomal readouts. This practical guide covers assay setup, dose-response design, orthogonal validation, and troubleshooting while separating product-specific evidence from a similarly named cardiovascular research compound.
-
Wnt Agonist 1: A Translational Test of Wnt Biology
2026-09-10
Wnt agonist 1, also known as BML-284, provides a practical pharmacological input for studying β-catenin–TCF signaling, cellular differentiation, and developmental biology. This thought-leadership article connects Wnt signaling pathway activation to the Wnt/NR2F2/GPX4 axis reported in lung cancer brain metastasis while outlining controls that can make translational experiments more rigorous.
-
Baicalin: Workflow for Adult Visual Plasticity
2026-09-09
Baicalin provides a practical pharmacological probe for testing whether adult visual-cortex inhibition can be reduced to restore ocular dominance plasticity. This workflow connects dose-controlled formulation, intrinsic signal optical imaging, electrophysiology, and mechanistic GABAergic assays while clearly separating vision-plasticity evidence from oncology applications.
-
Nullscript C3606: Reliable HDAC Assay Design
2026-09-09
Learn how Nullscript (SKU C3606), a histone deacetylase inhibitor, can support better-controlled viability, proliferation, cytotoxicity, and cardiac ischemia/reperfusion experiments. This scenario-based guide covers assay interpretation, stock preparation, vendor selection, and evidence limits.
-
Vernakalant for Rapid Atrial Fibrillation Conversion
2026-09-08
This phase 3 randomized trial evaluated vernakalant hydrochloride as a rapidly acting pharmacological strategy for converting atrial fibrillation to sinus rhythm. The study found substantially faster and more frequent conversion than placebo in patients with recent-onset AF, while also identifying hypotension and other clinically important adverse events that constrain interpretation and transferability.
-
GlycoRNA–RBP Surface Domains and Peptide Entry
2026-09-07
This preprint reports that cell-surface RNA-binding proteins and glycoRNAs organize into extracellular nanoclusters that support interaction with the cell-penetrating peptide TAT. Its perturbation experiments connect surface RNA to both cluster organization and peptide internalization, expanding the functional definition of the plasma membrane surface.
-
SFRP1, Wnt/β-Catenin, and Oral Fibrosis
2026-09-05
A 2024 study identifies SFRP1 as a potential molecular brake on oral submucous fibrosis by connecting reduced neutrophil infiltration with inhibition of canonical Wnt/β-catenin signaling. Using an arecoline-induced mouse model, SFRP1 overexpression, and pathway-rescue experiments, the work provides a mechanistic framework for studying inflammatory fibrosis while remaining preliminary for clinical translation.
-
HIV-1 Protease Autoprocessing in Drug Discovery
2026-09-05
Huang and colleagues developed a validated cell-based AlphaLISA assay that measures HIV-1 protease precursor autoprocessing rather than only mature protease activity. The platform selectively identified known autoprocessing inhibitors and reproduced resistance-associated effects, providing a practical route for screening compounds that act before mature protease release.